Hong Kong Stock Movement
160 HEALTH, down 15.05%. Based on recent key news:
<ol>
<li>
On May 6, 160 HEALTH's innovative applications in the AI medical field attracted market attention. The company has enhanced medical service efficiency by introducing AI intelligent technology, shortening product iteration cycles. The market's valuation logic has been in a tug-of-war between concept speculation and fundamental repair, leading to significant stock price fluctuations.
</li>
<li>
On May 6, 160 HEALTH was included in the Hong Kong Stock Connect, further driving stock price volatility. Inclusion in the Hong Kong Stock Connect has brought more investor attention to the company, and the market is full of expectations for its future development, resulting in substantial stock price fluctuations.
</li>
<li>
On May 6, 160 HEALTH's AI empowerment model has broad application prospects in public hospitals. The company is deeply cultivating the public hospital market through a platform + AI intelligent body + operation model, and the market is confident in its cost reduction and efficiency enhancement capabilities, intensifying stock price fluctuations. The innovative applications in the AI medical field have attracted attention.
</li>
</ol>
Stocks with High Trading Volume in the Industry
China National Pharmaceutical Group rose 0.16%. Based on recent news,
<ol>
<li>
On May 4, China National Pharmaceutical Group recorded a large transaction with a transaction amount of HKD 37.41 million. The transaction price was HKD 18.705, up 1.3% from the previous closing price, driving the stock price up.
</li>
<li>
On May 4, China National Pharmaceutical Group recorded a cross-trade of 2 million shares at 3:17 PM, with a price of HKD 18.705, resulting in a transaction amount of HKD 37.41 million, pushing the stock price up by 1.4%.
</li>
<li>
On May 4, China National Pharmaceutical Group's active buy-sell ratio was 40:60, with a net active sell of HKD 7.5269 million, indicating increased selling pressure on the stock. Market fund flow shows increased selling pressure.
</li>
</ol>
Shanghai Pharmaceuticals fell 0.66%. Based on recent news,
<ol>
<li>
On May 5, Goldman Sachs released a research report stating that Shanghai Pharmaceuticals' first-quarter revenue increased by 6.4% year-on-year to RMB 75.3 billion, and profit increased by 6.4% year-on-year to RMB 1.4 billion, with a slight expansion in gross profit margin from 10% in the same period last year to 10.4%. Goldman Sachs raised its net profit forecasts for 2026 to 2028 by 5%, 3%, and 3.6%, respectively, but maintained a &#34;Sell&#34; rating, raising the target price from HKD 10.3 to HKD 10.63. Goldman Sachs believes that under the normalization of bulk procurement of generic drugs and medical devices, the company's profit margins face greater pressure.
</li>
<li>
On May 5, Morgan Stanley released a research report stating that Shanghai Pharmaceuticals' first-quarter revenue was RMB 75.3 billion, a year-on-year increase of 6.4%, and net profit was RMB 1.418 billion, also a year-on-year increase of 6.4%, both in line with expectations. Morgan Stanley mentioned that Shanghai Pharmaceuticals is currently negotiating with multinational companies in the U.S. and EU regarding potential business development opportunities for its R&amp;D pipeline and gave a &#34;Market Perform&#34; rating with a target price of RMB 18.8
On May 6th, 36Kr reported that &#34;Beisai Hongsheng&#34; announced the completion of its A+ round financing, with funds primarily used to accelerate the preclinical and clinical research of multiple core R&amp;D pipelines, further solidifying the company's leading advantages in the two major technology platforms of induced pluripotent stem cells and tissue-specific small molecules. The pharmaceutical industry is facing profit margin pressures and needs to pay attention to policy changes.
</li>
</ol>
Baiyunshan rose by 0.84%. Based on recent news,
<ol>
<li>
On May 2nd, Guangzhou Pharmaceutical Group held a global investment promotion conference during the 139th Canton Fair, releasing clear investment policies and completing strategic agreements with several international and domestic partners, covering regions such as Southeast Asia and the Middle East. This move accelerated the layout of Guangzhou Pharmaceutical Group's brands in the international market, driving up stock prices.
</li>
<li>
On May 4th, Wanglaoji launched several new products in the UK market, with significant sales growth, and multiple categories saw sales double compared to the previous year. Wanglaoji's successful overseas strategy has provided strong support for Guangzhou Pharmaceutical Group's international layout, boosting market confidence.
</li>
<li>
On May 6th, Guangzhou Pharmaceutical Group unveiled the establishment of Guangzhou Pharmaceutical Capital Company, further deepening capital operations and showcasing the vigorous vitality of Chinese pharmaceutical brands. The continuous enhancement of brand value and the positive progress of the &#34;Four Transformations&#34; strategy have strengthened investors' confidence in the future development of Guangzhou Pharmaceutical Group. The international layout of the pharmaceutical industry is accelerating, and brand value is increasing.
</li>
</ol>
Stocks ranked among the top in industry market capitalization
Guanze Medical fell by 1.77%. Based on recent news,
<ol>
<li>
On May 4th, Guanze Medical Information Industry issued a clarification announcement, correcting the deadline for share registration to attend the annual shareholders' meeting. The new deadline is 4:30 PM on May 22, 2026. This announcement alleviated any concerns shareholders had regarding the administrative deadline, helping to ensure the standardization of corporate governance and the orderly participation in the annual shareholders' meeting.
</li>
<li>
On May 4th, the technical sentiment signal for Guanze Medical Information Industry indicated a buy, and despite the decline in stock prices, the market remains optimistic about its future performance.
</li>
<li>
There have been no other significant news recently. The medical information industry has shown stable performance recently, with optimistic market sentiment
</li>
</ol>

02656

160 HEALTH fell by 15.05%; Sinopharm Group rose by 0.16%, with a transaction volume of HKD 47.64 million; Shanghai Pharmaceuticals fell by 0.66%, with a transaction volume of HKD 33.07 million; Baiyunshan rose by 0.84%, with a transaction volume of HKD 15.24 million; GUANZE MEDICAL fell by 1.77%, with a market value of HKD 5.786 billion

HK Stock Alerts

160 HEALTH

SINOPHARM

SH PHARMA

BAIYUNSHAN PH

GUANZE MEDICAL

Hong Kong stock movement: 160 HEALTH fell by 15.05%, AI medical innovation and the inclusion of Hong Kong Stock Connect triggered significant market fluctuations